CRP and lung carcinoma: More recently, it has been reported that cytochrome P450 3A activity, the principal drug metabolising enzyme in a variety of chemotherapeutic agents, is compromised in advanced lung cancer patients with an elevated C-reactive protein concentration (Rivory et al, 2002; Slaviero et al, 2003).